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Abstract: Graves’ Disease (GD) is an autoimmune disease with higher prevalence in women than in men. The 
aim of the study was to correlate the expression of estrogen (ER) and progesterone receptors (PR) as well as Ki-
67 cell proliferation index in thyroid sections of GD and nodular goiter (ND) patients. The study was performed 
on archival paraffin blocks of 77 GD and 25 ND patients using immunohistochemistry. Higher expression of 
progesterone receptors (p = 0.0276) and Ki-67 index (p < 0.0001) was observed in thyroids of GD as compared 
to NG patients. No correlations were found between the particular markers and patients’ clinicopathological 
parameters, sex or age. A higher incidence of GD in women was not associated with different thyroid expression 
of ER and PR in comparison to men. No correlation was found between the expression of ER and PR and pro-
liferation marker of thyrocytes of GD and ND patients. Significantly higher expression of the Ki-67 antigen in 
GD lesions was observed as compared to the NG. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 2, 135–140)
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Introduction
Graves’ Disease (GD) is a common organ-specific au-
toimmune disorder of recurrent nature and complex 
pathogenesis involving genetic and environmental 
factors resulting in majority of the cases in hyperthyro-
idism [1]. Autoimmune diseases (AID) appear when 
the host immune system turns against its own antigens 
leading to dysfunction or destruction of tissues and 
organs. AID may develop in mechanisms involving 
immune deregulation, genetic predisposition and due 
to influence of environmental factors [2]. Thyroid 
autoimmune diseases like GD and Hashimoto thy-
roiditis (HT) affect the thyroid gland and are called 
autoimmune thyroid diseases (AITD). They are com-
plex diseases caused by an interaction of susceptibility 
genes and other, non-genetic factors like infection [1, 
3]. The background of GD appears to have a strong 
genetic nature associated with the polymorphism in 
the HLA, CTLA-4 (cytotoxic T-lymphocyte associa-
ted antigen-4) and protein tyrosine phosphatase type 
22 (PTPN22) genes but the pathogenesis is still not 
clear [1]. In GD thyroid-reactive T cells infiltrate the 
thyroid gland and activate B cells to produce thyro-
tropin receptor (TSHR) stimulating autoantibodies, 
leading to stimulation of thyroid follicular cells [3]. 
As a result, the negative control feedback loop of 
the pituitary system is superseded by the stimulating 
antibodies leading to constant thyrocyte activation via 
the TSHR and the production of thyroid hormones, 
thyroxine (T4) and triiodothyronine (T3) leading to 
hyperthyroidism [3]. 
Like other autoimmune diseases, GD appears 
more frequently in women than in men at a ratio of 
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7:1, which might suggest the role of hormonal fac-
tors in its pathogenesis [4]. Recent data showed that 
women are up to 7–10 times more likely susceptible 
to have GD, systemic lupus erythematous or Sjogren’s 
disease [5]. On the other hand, some other autoimmune 
diseases, e.g. rheumatoid arthritis or multiple sclerosis 
develop only 2-3 times more often in women than in men 
[5]. When unanticipated dimorphic findings appear be-
tween sexes, the first consideration is given to sex steroid 
hormones, which are known as potent mediators for sex 
differences. Sex steroid hormones include estrogens, 
progesterone and androgens and their action is depen-
dent upon their circulating blood levels and expression 
of congruent hormone receptors [5]. 
The protein, Ki-67 antigen is widely used as a 
marker of cell proliferation. Its precise function in 
cell proliferation is still unknown [6–10]. It was found 
that Ki-67 may be involved in perinuclear chromatin 
organization and its highest expression is noted in late 
G1, S and G2 phase of the cell cycle [6, 11]. In addition 
to its expression in proliferating cells, Ki-67 expression 
was also noted in processes associated with inhibited 
DNA synthesis or in the course of apoptosis [6, 11]. 
Despite some incoherent information concerning the 
biological significance of Ki-67 in cell physiology, this 
antigen is being currently routinely used as marker 
of cell proliferation in clinicopathological diagnostic 
methods, therefore it may also serve as a potent pro-
liferation marker of thyroid follicular cells [11–13].
The purpose of this retrospective study was to 
identify the association between the expression of es-
trogen receptors (ER), progesterone receptors (PR) 
in patients with GD to determine if these factors have 
influence on GD and its higher incidence in women. 
Moreover, the study aimed at examining the effects 
of ER and PR on proliferation rate of thyrocytes of 
GD patients, by assessing the expression of the Ki-67 
antigen.
Material and methods
Patients and tissue specimens. The study was performed 
on archival paraffin blocks of 77 patients with diagnosed 
GD and 25 patients with nodular goiter (ND), who were 
operated on at the Department of General, Gastroentero-
logical and Endocrinological Surgery of Wroclaw Medical 
University in the years 2003–2007. The mean age of patients 
with Graves’ disease was 38.89 ± 12.68 (range 16–68) years, 
whereas nodular goiter patients were aged 40.28 ± 12.1 
(range 21–61) years. In case of GD, 15 (19.5%) patients 
were male, whereas 62 (80.5%) were of female sex. In the 
NG group 6 (24.0%) patients were male and 19 (76.0%) 
were female. The study was approved by the Bioethical 
Commission of the Wroclaw Medical University.
Histopathological examination and immunohistochemical 
reactions (IHC). Tissue samples were fixed in 10% buffered 
formalin, dehydrated and embedded in paraffin blocks. 
For histopathological examination, the 6-µm sections were 
stained with hematoxylin and eosin (H&E) and reviewed by 
a pathologist to verify the diagnosis. Immunohistochemical 
reactions were performed on 4-µm-thick sections mounted 
on Superfrost Plus slides (Menzel Gläser, Braunschweig, 
Germany), deparaffinized in xylene and gradually rehy-
drated. Then, the sections were boiled in Target Retrieval 
Solution buffer (pH 6, 20 min; DakoCytomation, Glostrup, 
Denmark), subsequently cooled in distillate water and 
1×PBS. Sections were then incubated with 3% hydrogen 
peroxide for 5 min to block the endogenous peroxidase. 
Next, the sections were incubated with primary monoclonal 
antibodies directed against ER (clone 1D5, ready-to-use, 
specific for detecting only the type), PR (clone PgR 636, re-
ady-to-use) and Ki-67 (clone MIB1, ready-to-use) for 45 min 
in room temperature (DakoCytomation). The antigens were 
visualized using biotinylated antibodies and streptavidin 
conjugated with horseradish peroxidase (EnVision™ Mouse 
HRP, DakoCytomation). Diaminobenzidine (DAB, Dako-
Cytomation) was used as the substrate. All the reactions 
were conducted using negative controls and all the slides 
were counterstained with hematoxylin (DakoCytomation).
Evaluation of IHC reactions. The IHC sections were eva-
luated using BX-41 light microscope (Olympus, Tokyo, 
Japan) by two independent pathologists who were blinded 
to patients’ clinical data. In doubtful cases a re-evaluation 
was performed using a double-headed microscope and 
the staining was discussed until a consensus was achieved. 
ER, PR and Ki-67 antigen expression in follicular cells was 
assessed in whole tissue sections using a semiquantitative fi-
ve-point scoring system-based cell positivity. It was encoded 
as follows: 0 (0% cells stained), 1 (1–5% cells stained), 2 
(6–10% cells stained), 3 (11–20% cells stained), 4 (21–100% 
cells stained). 
Statistical analysis. The obtained results were subjected 
to statistical analysis using Prism 5.0 (GraphPad, La Jolla, 
US). The Shaphiro-Wilk normality test was used to assess 
the normality of the data distribution. Correlation between 
expression intensities of selected markers was examined 
using Spearman correlation test. The Mann-Whitney U 
test was applied to compare the differences in expression of 
the studied markers between the groups. The results were 
considered significant at p < 0.05.
Results
Nuclear expression of ER, PR and Ki-67 was observed 
in thyrocytes of patients with GD and compared to 
their expression in patients with NG (Figure 1). The 
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distribution of the studied markers in both studied 
groups was summarized in Table 1. We noted a si-
gnificantly higher PR expression in GD as compared 
to ND (1.23 ± 1.31 vs. 0.56 ± 0.82; p = 0.0276; Figure 
2A). Thyrocytes affected in the GD exerted also higher 
Figure 1. Low (A, C) and high (B, D) nuclear expression of PR (A, B) and ER (C, D) in thyroids of Graves’ disease pa-
tients. Arrowheads indicate positive nuclear reaction. Magnification × 400
Table 1. Distribution of ER, PR and Ki-67 in thyrocytes of Graves’ disease and nodular goiter patients
IHC marker score Graves’ disease No. cases (%) Nodular goiter No. cases (%) All patients 
No. cases (%)
ER
0 (0%) 36 (46.7) 8 (32.0) 44 (43.1)
1 (1–5%) 19 (24.7) 12 (48.0) 31 (30.4)
2 (6–10%) 12 (15.6) 4 (16.0) 16 (15.7)
3 (11–20%) 6 (7.8) 1 (4.0) 7 (6.9)
4 (21–100%) 4 (5.2) 0 (0.0) 4 (3.9)
PR
0 (0%) 32 (41.6) 15 (60.0) 47 (46.1)
1 (1–5%) 16 (20.8) 7 (28.0) 23 (22.5)
2 (6–10%) 13 (16.8) 2 (8.0) 15 (14.7)
3 (11–20%) 11 (14.3) 1 (4.0) 12 (11.8)
4 (21–100%) 5 (6.5) 0 (0.0) 5 (4.9)
Ki-67
0 (0%) 19 (24.6) 19 (76.0) 38 (37.4)
1 (1–5%) 41 (53.3) 5 (20.0) 46 (45.1)
2 (6v10%) 12 (15.6) 0 (0.0) 12 (11.6)
3 (11–20%) 3 (3.9) 1 (4.0) 4 (3.9)
4 (21–100%) 2 (2.6) 0 (0.0) 2 (2.0)
IHC — immunohistochemical, IHC scores were estimated as described in Material and methods
A B
C D
proliferation rate in comparison to NG as measured by 
the expression of the Ki-67 antigen (1.07 ± 0.89 vs. 0.32 
± 0.69; p < 0.0001; Figure 2B). No differences were 
noted between the two groups regarding the ER expres-
sion (GD: 1.00 ± 1.19 vs. ND: 0.92 ± 0.81; p = 0.7349).
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No significant correlations were noted between 
the studied markers and patients age in the particular 
study groups and when both groups were analyzed 
together (Spearman correlation test). Expression 
intensities of the studied markers did not differ re-
garding patients age and sex in GD and NG lesions. 
Moreover, no differences in patients age and sex were 
observed between the two analyzed lesions.
Discussion
In this study we have investigated the association 
between expression of ER and PR in patients with 
GD to determine whether these factors may have in-
fluence on the proliferation of thyrocytes and overall 
higher incidence of GD in women. We found higher 
level of PR expression in thyrocytes of GD patients 
in comparison to NG patients. Moreover, we noted 
a significantly higher expression of the Ki-67 antigen 
in GD lesions as compared to the NG.
Cellular responses to sex hormones are dependent 
on the expression of hormone receptors that include 
two types of ER, PR and androgen receptors. Cu-
rrently, the data concerning the expression of these 
receptors in thyrocytes of GD remain obscure. In 
women progesterone plays an important role during 
pregnancy. Its elevated levels keep the uterus in com-
plete quiescence, acting through its nuclear PR [14]. 
Progesterone is also known for its anti-inflammatory 
role in human myometrial cells, as it acts antagonisti-
cally to NF-kB activation and induces cyclooxygenase 2 
expression, the crucial enzyme in prostaglandin produc-
tion and inflammation [14]. Therefore, progesterone 
besides its endocrine effects in pregnancy, acts as an 
‘immunosteroid’ with local immunosuppressant functions 
[15]. Progesterone acts through PR via the induction of 
Progesterone Induced Blocking Factor (PIBF), which in 
turn may affect B lymphocytes. In result, the interleukin 
expression profile of these cells switches to a more non-
cytotoxic, therefore supporting the immunosuppressive 
role of progesterone and the PR [16].
Interestingly, in our study we observed the incre-
ased expression of PR receptors in GD patients as 
compared to NG patients. PR expression was also 
studied in rheumatoid arthritis (RA), a disease with 
higher prevalence in women [17]. Ishizuka et al. [17] 
found a significant difference in the relative expres-
sion levels of progesterone receptor type B (PR-B) 
in synovial tissue. In light of those results, it seems 
that elevated PR in thyrocytes of GD patients may 
represent a protective, immunosuppressive mecha-
nism in this disease, but further research should be 
undertaken with inclusion of patients detailed clinical 
data to clarify such a hypothesis. 
Two types ER are recognized, the estrogen recep-
tor a (ERa) encoded by ESR1 gene (locus 6q25.1) 
and estrogen receptor b (ER b), which is encoded by 
the ESR2 gene (locus 14q23), which mediate actions 
of estrogen in multiple tissues [1]. The ESR2 gene 
is situated close to the GD locus at 14q31 [3, 18]. 
In our study we estimated the expression of ERa, 
however, we failed to note any significant differen-
ces in its expression in GD and NG. The ERa was 
shown to promote proliferation in the tissue of the 
uterus, mammary gland and cells of the immune 
system [4, 19], therefore we analyzed its expression 
in GD thyroids. Until now, only one study analyzed 
the relationship between the ER in thyroid cells of 40 GD 
patients and compared to its expression noted in 
15 control cases encompassing healthy thyroid tissu-
es [20]. In contrast to the results obtained by us on 
a larger patients cohort, Wang et al. found a significant 
correlation between ERa expression in GD thyrocytes 
as compared to normal thyroid [20]. Although in our 
study we did not noted any significant differences 
in ER expression between GD and NG, we may not 
directly compare our results with the results obtained 
Figure 2. Differences in the expression of PR (A) and Ki-67 
antigen (B) between the Graves’ disease and nodular goiter 
patients. *p < 0.05; ****p < 0.0001 (Mann-Whitney test)
139ER, PR and Ki-67 in Graves’ disease
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2013
10.5603/FHC.2013.0021
www.fhc.viamedica.pl
by Wang et al. as the ER expression of ER was not 
studied in NG lesions [20]. The results of  studies 
analyzing ER expression in NG were inconsistent, as 
some studies reported even higher ER expression as 
this noted in our studies, whereas some did not report 
ERa expression in thyrocytes [21–23]. Studies aimed 
at examining the associations between ER and GD 
found, that the ESR2 gene was not associated with GD 
incidence in the Japanese population [24], whereas 
in the Polish study of Kisiel et al., the authors found 
a significant association between this gene and GD 
susceptibility [1]. To note, these studies were perfor-
med on isolated blood cells [1, 24], whereas in our 
study performed on thyroid sections of GD and NG 
patients the ERa expression was associated neither 
with patient sex nor age.
Lines of evidence suggest that pathogenesis of 
autoimmune diseases may involve a specific effect 
of sex steroid hormones on the immune system [5]. 
The effects of steroid hormones on immune system 
are heterogeneous. They may act as immunosuppres-
sors as well as immunostimulators, and the balance 
between these two processes seems to be dependent 
upon steroid hormones levels. The higher incidence 
of AID in women seems to be linked to influence of 
sex steroid hormones on autoimmunity, as ER and PR 
were reported to be expressed also on some types of 
immune cells [5, 25, 26]. This may partly explain the 
higher incidence of AID noted in woman. Moreover, 
women have more vigorous cellular and humoral 
immune reactions than men [28]. Receptor-mediated 
effects of steroids on immune system are not well 
elucidated. Generally, estrogens are regarded as en-
hancers of immune response whereas androgens and 
progestins have an immunosuppressive effect [5]. Sex 
hormones were shown to play a role in autoimmune 
diseases by the modulation of cell proliferation and 
cytokine production of various cell types, including 
the cells of the immune systems [4, 19, 27]. Our study 
suggests that the expression of ER and PR in thyrocy-
tes of GD patients has no impact on the proliferation 
of thyrocytes as measured by the expression of the 
Ki-67 antigen, despite significantly higher expres-
sion of this proliferation marker in GD patients as 
compared to NG patients. However, the role of ER 
and PR expression in immune cells of GD patients 
remains to be elucidated, as this study addressed only 
the issue of their expression in thyrocytes, but not the 
surrounding immune cells.
In summary, we showed that ER and PR expres-
sion in thyrocytes of GD patients plays a limited role 
in the pathogenesis of this disease. Moreover, the 
expression of ER and PR in GD and NG patients had 
no impact on the proliferation of thyrocytes.
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